In the May 2018 Budget the Government proposed a series of changes to the R&D Tax Incentive which would further reduce the support it provides to private sector R&D activity. While advocacy by Research Australia and others has succeeded in having clinical trial expenditure by small companies exempted form the cuts, several of the other changes remain a concern. Research Australia’s submission to the Senate Inquiry on the new legislation has put the case for why the cuts should be rejected by the Senate.
Research Australia’s Collaborative Strategy and Priority Projects are now available for you to download and share.
Research Australia envisions a world where Australia unlocks the full potential of its world-leading health and medical research sector to deliver the best possible healthcare and global leadership in health innovation.
Connecting researchers, funders, and consumers to increase investment in health and medical research from all sources.
Engaging Australia in a conversation about the health benefits and economic value of its investment in health and medical research.
Influencing government policies that support effective health and medical research and its routine translation into evidence-based practices and better health outcomes.
To use our unique convening power to position health and medical research as a significant driver of a healthy population and contributor to a healthy economy.
Australian clinical trials received a much-needed boost today with details of the Medical Research Future Fund’s disbursements announced.
The Minister for Health, Greg Hunt announced the detail around the allocation of the funding into clinical trials in Australia that was handed down at the Budget last Tuesday as part of the Medical Research Future Fund (MRFF).
As the Health and Medical Research industry body, we were pleased to hear the importance the Australian Government has placed on clinical trials, collaboration, and translation of research and mid-career medical researchers.
“Clinical trials are a crucial part of changing and saving lives,” said Research Australia CEO, Nadia Levin. “This commitment goes a long way in making a difference to Australians whose lives depend on the outcomes of the best research we can offer”.
The announcement was made at the Royal Prince Alfred Hospital in Sydney at an event to celebrate International Clinical Trials Day.
Continue reading “Funding boost from MRFF for clinical trials”
Research Australia’s submission in response the draft Fifth National Mental Health Plan has highlighted the Plan’s failure to include health and medical research.
Research Australia is concerned that the Fifth Plan is currently a missed opportunity to make better use of Australia’s significant capacity in health and medical research to help deliver the Plan’s vision of healthier Australians, faster and more complete recoveries from mental illness and more responsive and effective services.
The draft Fifth Plan calls for significant reform and innovation in the way we deliver mental health services in Australia, and the health and medical research sector is well placed to help inform, design, implement and evaluate these reforms. Research Australia believes the Fifth Plan provides an opportunity to improve the integration of the mental health system with the health and medical research sector, and to better utilise and direct research towards the Plan’s priorities. Our submission has highlighted some of the many ways in which health and medical research can contribute. Submission for 5th Mental Health Plan
Media Release: Friday 20 May 2016
A clinical trial investigating reducing risk of neonatal infections related to pre-labour ruptured membranes, has been awarded the inaugural Trial of the Year Award 2016 by the Australian Clinical Trials Alliance (ACTA).
Professor Johnathan Morris, chief investigator, this morning accepted the award on behalf of the trial investigators at the Clinical Trials 2016 Breakfast and Award Ceremony this morning from Health Minister Sussan Ley.
The Michael J. Fox Foundation‘s Co-Founder Debi Brooks breaks down the pharmaceutical development landscape in an easy to understand analogy and explains how the Foundation plays a critical role in bringing better and improved Parkinson’s disease therapies to patients.
Prostate Cancer Foundation Australia (PCFA) and the Movember Foundation have today announced funding towards two new clinical trials to address significant research questions that will potentially revolutionise the way prostate cancers are monitored and treated. These clinical trials involve the testing of a new scanning technique and the role of Vitamin D in preventing progression of prostate cancer.
Clinical trials are conducted in human volunteers to test that new drugs, devices and therapies (‘interventions’) are safe and effective. A new compound may kill tumour cells in mice, but will it work effectively in people, and how big a dose is required? Can it be delivered as a tablet, or is an injection more effective? These are some of the questions that can only be answered with a clinical trial. For people with hard to treat diseases, participation in a clinical trial for a new drug may offer the only opportunity for a cure.
Clinical trials also provide the opportunity to compare the effectiveness of existing treatments or practices, to determine if they actually work, and which is best.
Clinical trials in Australia are subject to strict rules to protect participants and ensure the integrity of the trial process, so that the results can be relied on when deciding whether to allow a new intervention to be offered to patients in Australia, or whether existing practices should be changed.
The NHMRC has consulted on a Good Practice Process for Clinical Trials with the aim of improving clinical trials governance. Research Australia has made a submission welcoming the initiative and acknowledging that it is one of a number of actions being undertaken to improve, standardise and streamline clinical trial processes, including by COAG’s Standing Committee on Health. Research Australia’s submission highlights the benefits of moving to a national, standardised approach to clinical trials, points to some possible improvements to the process and identifies some state- specific regulatory barriers.
The South Australian Government issued a discussion paper seeking on the suitability of Social Impact Bonds to fund innovative new programs. Research Australia’s submission proposes the use of Social Impact Bonds to address the well recognised problem of translating research outcomes and discoveries into practice in the health system. Specifically, Research Australia believes that Social Impact Bonds could be an effective mechanism for funding and evaluating pilot projects and clinical trials designed to implement and evaluate new evidence based practices and interventions. The benefits of implementing successful new interventions are improved patient care and efficiency gains in the South Australian health care system.